Schlagwort: Impact Life Sciences
‘What needs to catch up is the speed of translation from...
Crelux has grown from a structural biology company into a multidisciplinary discovery hub within WuXi AppTec. Dr Thomas Meins discusses accelerating drug discovery, helping...
‘We want to go from being top-class in research to being...
Germany has world-class health research, but turning scientific excellence into market success requires more private capital. Federal Minister of Research, Technology and Space Dorothee...
‘Approach Saudi Arabia as a long-term partner rather than simply as...
Saudi Arabia is positioning itself as a life sciences hub with capital, healthcare scale, and a clear biotechnology strategy. In this interview, Bandar Alknawy...
Out now: Impact Life Sciences special edition
In our new Impact Life Sciences special edition, we take a closer look at the dynamic development of the biotechnology and life sciences sector...
„Driving biotech in Europe“ – BayOConnect 2026 bringt führende Akteure zusammen
Vom 30. Juni bis zum 01. Juli 2026 stand die bayerische Hauptstadt Bayern im Zeichen der europäischen Biotechnologie. Zur dritten BayOConnect – Forum for...
Für mehr Innovation im Biotech-Sektor: Ludwig-Maximilians-Universität München und Life Science Factory...
Die Ludwig-Maximilians-Universität München (LMU) und die Life Science Factory München haben eine strategische Partnerschaft geschlossen. Ziel ist es, Forschung, Gründung und unternehmerische Umsetzung im...
Mehr als 200 Branchengrößen unterzeichnen offenen Brief der European Life Sciences...
Der europäische Private-Equity- und Venture-Capital-Investor Andera Partners wird Mitglied der European Life Sciences Coalition (ELSC). Die gemeinsam mit Invest Europe ins Leben gerufene Initiative...
Pioneering quantum health
Fresh capital and a strategic pivot: how Ulm-based deeptech company NVision is transforming from a sensing hardware provider into a holistic ‘compute and validate’...
‘Copper theranostics bring diagnosis and treatment together in a highly effective...
Dr Leila Jaafar-Thiel, CEO of Nuclidium, explains how the company’s copper-based radiotheranostic approach will become a milestone in precision oncology for an improved individual...
Now online: Special „Impact Life Sciences 02/26“!
The market for Contract Development and Manufacturing Organisations (CDMOs) and Contract Research Organisations (CROs) continues to grow strongly. As biotechnology companies increasingly outsource development...
GeneNovate Investors’ Day: Investitionen in die Zukunft der Gen- und Zelltherapien
Die Entwicklung gen- und zellbasierter Therapien gehört zu den bedeutendsten
Innovationstreibern der modernen Medizin. Während klassische Arzneimittel häufig Symptome behandeln oder Krankheitsverläufe verlangsamen, eröffnen Gen-...
Impact Life Sciences Deep Dive 2026
Am 22. Juni 2026 veranstalten wir gemeinsam mit EY in München (invite only) den ersten Impact Life Sciences Deep Dive 2026. Freuen Sie sich...
Germany is emerging as a hub for nuclear medicine
Theranostics is on the rise and is becoming an exciting investment opportunity for private equity firms and other investors. In Germany, the Dresden’s Radiopharmaceutical...
The ultimate funding hack? A real value proposition and strong industry...
Public funding mitigates risks, but it cannot replace equity. Life sciences founders who merely jump from one funding deadline to the next, or who...